NCT03953235 - A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

March 10, 2023

Study Completion Date

March 10, 2023

Conditions

Non-Small Cell Lung CancerColorectal CancerPancreatic CancerSolid TumorShared Neoantigen-Positive Solid Tumors

Interventions

BIOLOGICAL

GRT-C903

a shared neoantigen cancer vaccine prime

BIOLOGICAL

GRT-R904

a shared neoantigen cancer vaccine boost

BIOLOGICAL

nivolumab

anti-PD-1 monoclonal antibody

BIOLOGICAL

ipilimumab

anti-CTLA-4 monoclonal antibody

Trial Locations (12)

10032

Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

19111

Fox Chase Cancer Center, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

32224

Mayo Clinic Florida, Jacksonville

37203

Tennessee Oncology, Nashville

43210

The Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic Rochester, Rochester

60637

University of Chicago Medicine, Comprehensive Cancer Center, Chicago

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic Arizona, Phoenix

90404

UCLA Medical Center, Santa Monica